Literature DB >> 28918384

Systematic review and meta-analysis of effectiveness of preoperative embolization in surgery for metastatic spine disease.

Panya Luksanapruksa1, Jacob M Buchowski2, Sasima Tongsai3, Weerasak Singhatanadgige4, Jack W Jennings5.   

Abstract

BACKGROUND: Preoperative embolization (PE) may decrease intraoperative blood loss (IBL) in decompressive surgery of hypervascular spinal metastases. However, no consensus has been found in other metastases and no meta-analysis which reviewed the benefit of PE in spinal metastases has been conducted.
OBJECTIVE: To assess IBL in spinal metastases surgery in a randomized controlled trial (RCT) and cohort studies comparing PE and a control group of non-embolized patients.
METHODS: A systematic search of relevant publications in PubMed and EMBASE was undertaken. Inclusion criteria were RCTs and observational studies in patients with spinal metastases who underwent spine surgery and reported IBL. Meta-analysis was performed using standardized mean difference (SMD) and mean difference (MD) of IBL. Heterogeneity was assessed using the I2 statistic.
RESULTS: A total of 265 abstracts (126 from PubMed and 139 from Embase) were identified through database searching. The reviewers selected six studies for qualitative synthesis and meta-analysis. The pooled SMD of the included studies was 0.58 (95% CI -0.10 to 1.25, p=0.09). Sensitivity analysis revealed that, if the study by Rehak et al was omitted, the pooled SMD was significantly changed to 0.88 (95% CI 0.39 to 1.36, p<0.001) and PE reduced the IBL significantly. The pooled MD was 708.3 mL (95% CI -224.4 to 1640.9 mL, p=0.14). If the results of the Rehak et al study were omitted, the pooled MD was significantly changed to 1226.9 mL (95% CI 345.8 to 2108.1 mL, p=0.006).
CONCLUSIONS: PE can be effective in reducing IBL in spinal metastases surgery in both renal cell carcinoma and mixed primary tumor groups. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  epidural; metastatic; neoplasm; spine

Mesh:

Year:  2017        PMID: 28918384     DOI: 10.1136/neurintsurg-2017-013350

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836


  5 in total

1.  Does the anatomical region predict blood loss or neurological deficits in embolized renal cancer spine metastases? A single-center experience with 31 patients.

Authors:  Anna Voelker; Georg Osterhoff; Stefanie Einhorn; Sebastian Ebel; Christoph-Eckhard Heyde; Philipp Pieroh
Journal:  World J Surg Oncol       Date:  2022-06-16       Impact factor: 3.253

2.  Preoperative embolization of hypervascular spinal tumors: Two case reports.

Authors:  Nguyen Thai Binh; Tran Quoc Hoa; Le Tuan Linh; Thieu-Thi Tra My; Pham Quynh Anh; Nguyen Minh Duc
Journal:  J Clin Imaging Sci       Date:  2022-05-02

3.  Only Tumors Angiographically Identified as Hypervascular Exhibit Lower Intraoperative Blood Loss Upon Selective Preoperative Embolization of Spinal Metastases: Systematic Review and Meta-Analysis.

Authors:  Yining Gong; Changming Wang; Hua Liu; Xiaoguang Liu; Liang Jiang
Journal:  Front Oncol       Date:  2021-01-19       Impact factor: 6.244

4.  Trends in Utilization of Preoperative Embolization for Spinal Metastases: A Study of the National Inpatient Sample 2005-2017.

Authors:  Waseem Wahood; Alex Yohan Alexander; Yagiz Ugur Yolcu; Waleed Brinjikji; David F Kallmes; Giuseppe Lanzino; Mohamad Bydon
Journal:  Neurointervention       Date:  2021-02-04

Review 5.  Evaluating the Optimal Management of Inoperable Giant Cell Tumors of the Spine: A Systematic Review and Meta-Analysis.

Authors:  Paolo Palmisciano; Gianluca Ferini; Andrew L Chen; Kishore Balasubramanian; Abdurrahman F Kharbat; Navraj S Sagoo; Othman Bin Alamer; Gianluca Scalia; Giuseppe E Umana; Salah G Aoun; Ali S Haider
Journal:  Cancers (Basel)       Date:  2022-02-14       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.